• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    1/25/24 4:31:04 PM ET
    $AFIB
    $CASI
    $CVRX
    $IVP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AFIB alert in real time by email

    Gainers

    • Inspire Veterinary (NASDAQ:IVP) stock moved upwards by 37.5% to $0.26 during Thursday's after-market session. The market value of their outstanding shares is at $2.8 million.
    • Tharimmune (NASDAQ:THAR) stock rose 16.5% to $0.53. The market value of their outstanding shares is at $1.3 million.
    • MyMD Pharmaceuticals (NASDAQ:MYMD) shares increased by 8.28% to $0.18. The company's market cap stands at $9.1 million.
    • Shuttle Pharmaceuticals (NASDAQ:SHPH) stock increased by 8.2% to $0.43. The market value of their outstanding shares is at $6.9 million.
    • Windtree Therapeutics (NASDAQ:WINT) stock rose 6.12% to $0.47. The company's market cap stands at $3.0 million.
    • BiomX (AMEX:PHGE) shares moved upwards by 5.37% to $0.26. The company's market cap stands at $11.7 million.

    Losers

    • Processa Pharma (NASDAQ:PCSA) stock decreased by 14.7% to $4.35 during Thursday's after-market session. The market value of their outstanding shares is at $5.3 million.
    • CASI Pharmaceuticals (NASDAQ:CASI) stock decreased by 14.02% to $6.75. The company's market cap stands at $89.9 million.
    • CVRx (NASDAQ:CVRX) stock fell 13.53% to $25.25. The market value of their outstanding shares is at $525.5 million. As per the press release, Q4 earnings came out today.
    • PTC Therapeutics (NASDAQ:PTCT) stock decreased by 13.21% to $23.14. The company's market cap stands at $1.7 billion.
    • Acutus Medical (NASDAQ:AFIB) stock fell 12.91% to $0.27. The market value of their outstanding shares is at $7.9 million.
    • Petros Pharma (NASDAQ:PTPI) stock fell 10.53% to $1.02. The company's market cap stands at $2.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AFIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AFIB
    $CASI
    $CVRX
    $IVP

    CompanyDatePrice TargetRatingAnalyst
    PTC Therapeutics Inc.
    $PTCT
    1/28/2026$119.00Overweight
    Barclays
    PTC Therapeutics Inc.
    $PTCT
    12/1/2025$91.00Outperform → Sector Perform
    RBC Capital Mkts
    PTC Therapeutics Inc.
    $PTCT
    10/20/2025$73.00Overweight
    Wells Fargo
    PTC Therapeutics Inc.
    $PTCT
    6/17/2025$80.00Buy
    Truist
    CVRx Inc.
    $CVRX
    5/9/2025$7.00Neutral → Underweight
    Analyst
    PTC Therapeutics Inc.
    $PTCT
    5/9/2025$68.00Neutral → Buy
    BofA Securities
    PTC Therapeutics Inc.
    $PTCT
    5/7/2025$40.00Sell → Neutral
    Citigroup
    PTC Therapeutics Inc.
    $PTCT
    3/11/2025$41.00 → $55.00Underperform → Neutral
    BofA Securities
    More analyst ratings

    $AFIB
    $CASI
    $CVRX
    $IVP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jain Mudit K. bought $297,592 worth of shares (46,800 units at $6.36) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/23/26 6:00:12 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Jain Mudit K. bought $2,785 worth of shares (600 units at $4.64), increasing direct ownership by 12% to 5,650 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/18/26 5:22:25 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Executive Chairman Gravitas Capital Lp bought $500,000 worth of shares (337,838 units at $1.48), increasing direct ownership by 86% to 732,424 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 9:29:23 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $CASI
    $CVRX
    $IVP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Yeganeh Reuven

    4 - BiomX Inc. (0001739174) (Issuer)

    3/18/26 5:47:41 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Adamson Philip B. was granted 41,000 shares and sold $9,973 worth of shares (1,262 units at $7.90), increasing direct ownership by 182% to 61,578 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    3/16/26 4:16:14 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CHIEF EXECUTIVE OFFICER Klein Matthew B. was granted 12,500 shares and sold $170,581 worth of shares (2,662 units at $64.08), increasing direct ownership by 3% to 396,920 units (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    3/13/26 5:20:05 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $CASI
    $CVRX
    $IVP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BiomX CEO Issues Letter to Stockholders

    CEO Letter to Stockholders highlights the Company's strategic and financial reset designed to strengthen BiomX in the near term and unlock future growth opportunitiesDOVER, Del., March 19, 2026 /PRNewswire/ -- BiomX Inc. (NYSE:PHGE), today released the following letter from its Chief Executive Officer to stockholders. Dear Stockholders,Over the past several weeks, BiomX has taken decisive steps to reshape its leadership, priorities, and financial structure. Leadership has evolved, strategic priorities have been sharpened, and we are taking concrete steps intended to improve the Company's financial and operational structure. These changes have not been easy, but they are necessary to put Biom

    3/19/26 9:15:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WARREN, N.J., March 13, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that on March 10, 2026, the company approved non-statutory stock options to purchase an aggregate of 14,550 shares of its common stock and 17,515 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 18 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on Marc

    3/13/26 4:30:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    E.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals' $3.5 Million Public Offering

    NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. ("E.F. Hutton"), a leading investment banking and financial advisory firm, today announced that it acted as the exclusive placement agent in connection with a $3.5 million public offering by Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharmaceuticals" or the "Company"), the owner of Molecule.ai, an artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development. Shuttle Pharmaceuticals entered into a securities purchase agreement with investors for the issuance and sale of 2,238,800 shares of common stock and pre-funded warrants to purchase 4,761,200 shares of common s

    3/12/26 8:30:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $CASI
    $CVRX
    $IVP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AFIB
    $CASI
    $CVRX
    $IVP
    SEC Filings

    View All

    BiomX Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BiomX Inc. (0001739174) (Filer)

    3/19/26 9:25:39 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Processa Pharmaceuticals Inc.

    10-K - Processa Pharmaceuticals, Inc. (0001533743) (Filer)

    3/18/26 4:05:57 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BiomX Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - BiomX Inc. (0001739174) (Filer)

    3/11/26 4:24:30 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AFIB
    $CASI
    $CVRX
    $IVP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on PTC Therapeutics with a new price target

    Barclays resumed coverage of PTC Therapeutics with a rating of Overweight and set a new price target of $119.00

    1/28/26 7:18:18 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded PTC Therapeutics from Outperform to Sector Perform and set a new price target of $91.00

    12/1/25 8:18:44 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on PTC Therapeutics with a new price target

    Wells Fargo initiated coverage of PTC Therapeutics with a rating of Overweight and set a new price target of $73.00

    10/20/25 8:02:41 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $CASI
    $CVRX
    $IVP
    Leadership Updates

    Live Leadership Updates

    View All

    BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth

    Seasoned financial leaders join BiomX to support strategic execution and advancement of the companyDOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/ -- BiomX Inc. (NYSE:PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, today announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer. Oster brings extensive experience in corporate strategy, mergers and acquisitions, and operational leadership across capital-intensive industries including energy, infrastructure, and industrial sectors. Throughout his career, he has led complex

    3/9/26 9:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

    New Directors Strengthen Governance as Company Advances Canton Network Infrastructure Former CFTC Commissioner Jill Sommers Brings Decades of Regulatory and Public Policy Experience DRW Chief of Staff William Wiley, CFA, Adds Extensive Leadership Experience Across Capital Markets and Global Operations NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Jill Sommers and William Wiley, CFA, to the Board, effective February 1, 20

    2/2/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $CASI
    $CVRX
    $IVP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

    SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

    11/14/24 7:15:44 PM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

    SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    11/14/24 5:22:11 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $CASI
    $CVRX
    $IVP
    Financials

    Live finance-specific insights

    View All

    PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    – Full-year 2025 product and royalty revenue of $831M, exceeding guidance –– Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respectively –– Cash of $1.95B as of December 31, 2025 –WARREN, N.J., Feb. 19, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2025.  "We delivered another strong quarter and finish to 2025, building on the successful global launch of Sephience," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "With our robust commercial engine, innovative R&D programs,

    2/19/26 4:01:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2025. Recent Highlights Total revenue for the fourth quarter 2025 was $16.0 million, an increase of 4% over the prior year quarterU.S. revenue for the fourth quarter of 2025 was $14.9 million, an increase of 4% over the prior year quarterTotal revenue for 2025 was $56.7 million, an increase of 10% over the prior yearActive implanting centers

    2/12/26 4:05:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026

    WARREN, N.J., Feb. 5, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year 2025 financial results and provide an update on the company's business and outlook on Thursday, Feb. 19, 2026, at 4:30 p.m. ET. To access the call by phone, please click here to register and you will be provided with dial-in details. The webcast conference call can be accessed on the Investors section of the PTC website at https://ir.ptcbio.com/events-presentations. A replay of the call w

    2/5/26 8:00:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care